Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
There is an urgent need for new antibiotics to treat multidrug-resistant Neisseria gonorrhoeae In this report, the microbiology, in vivo pharmacokinetics, and efficacy of REDX05931, a representative novel tricyclic topoisomerase inhibitor, were evaluated. REDX05931 demonstrated high oral bioavailability in mice and reduced N. gonorrhoeae infection after a single dose in a mouse model of gonorrhea. These data support the potential of this series of small molecules as a new treatment for drug-resistant gonorrheal infections.
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Victoria J
VJ
Savage
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Cédric
C
Charrier
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Anne-Marie
AM
Salisbury
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Helen
H
Box
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Nathan
N
Chaffer-Malam
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Anthony
A
Huxley
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Ralph
R
Kirk
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Gary M
GM
Noonan
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Sarfraz
S
Mohmed
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Mark W
MW
Craighead
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Andrew J
AJ
Ratcliffe
Redx Pharma, Alderley Park, Cheshire, United Kingdom.
Stuart A
SA
Best
Redx Pharma, Alderley Park, Cheshire, United Kingdom n.stokes@redxpharma.com.
Neil R
NR
Stokes
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D006069:Gonorrhea / Q000188:drug therapy* / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D059003:Topoisomerase Inhibitors / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D059003:Topoisomerase Inhibitors